HAIC combined with atezolizumab and bevacizumab versus lenvatinib in advanced hepatocellular carcinoma: a multicenter propensity score matching analysis
Lei Zhao, Dan Liu, Chao Ma, Yue Hu, Shu Liu · 2026
Read HAIC combined with atezolizumab and bevacizumab versus lenvatinib in advanced hepatocellular carcinoma: a multicenter propensity score matching analysis by Lei Zhao, Dan Liu, Chao Ma, Yue Hu, Shu Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13547088.txt.
Description
Lei Zhao and co-authors compared two drug combinations in 2026 for advanced liver cancer across several centers. Both pair a liver artery chemotherapy infusion with a second agent: immune therapy drugs in one arm, a targeted pill in the other. Records held 306 patients; matching balanced the groups at 106 each. Survival was the main measure.
The immune combination gave notably longer median survival, about twenty-six months against sixteen. Time without growth and response rates were alike between groups. Side effects were similar and manageable, with none fatal. The authors favor the immune pairing for advanced cases. The study is retrospective, so a trial would firm the claim.
Catalog record
| CREATOR | Lei Zhao, Dan Liu, Chao Ma, Yue Hu, Shu Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |